| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Otolaryngology [B. W. L., W-D. Y., M. C. M., D. M. R., C. S. J.], Medicine [D. L. T.], and Pharmacology [C. S. J.], University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213
In a murine squamous cell carcinoma (SCC) model, we have demonstrated that both 1,25-dihydroxycholecalciferol (1,25-D3) and the analogue 1,25-dihydroxy-16-ene-23-yne-cholecalciferol (Ro23-7553) have significant in vitro and in vivo antitumor activity. We have examined here the cell cycle effect of 1,25-D3 and Ro23-7553 on SCCVII/SF tumor cells by quantitating nuclear DNA using a detergent-trypsin method via flow cytometry analysis. Both 1,25-D3 and Ro23-7553 resulted in a significant increase of cells in G0-G1, with an accompanying decrease of cells in S phase. The ability to arrest cells in G0-G1 has been exploited by combining Ro23-7553 with the cytotoxic agent cisplatin (cis-diamminodichloroplatinum; cDDP). Using the in vitro clonogenic assay, pretreatment with Ro23-7553 for 24–48 h significantly enhanced cDDP-mediated tumor cell kill as compared to concurrent treatment with Ro23-7553 and cDDP or cDDP alone. To examine the effect of Ro23-7553 and cDDP in vivo, C3H/HeJ mice with 9–14-day SCC tumors were treated either for 3 days with varying i.p. doses of Ro23-7553 or for 7 days continuously through the use of Alzet pumps, and on the last day of Ro23-7553 treatment, cDDP (1–6 mg/kg) was administered. Using the in vivo excision tumor cell clonogenic assay, in which tumors were removed from animals 24 h after cDDP treatment and plated in a clonogenic assay, pretreatment with Ro23-7553 markedly enhanced cDDP-mediated clonogenic tumor cell kill, even at low doses of cDDP as compared to cDDP treatment alone. Similarly, a significant decrease in fractional tumor volume and increase in tumor regrowth delay was observed when animals were pretreated before cDDP with Ro23-7553 as compared to either agent alone. These results demonstrate a significant enhanced antitumor effect with Ro23-7553 pretreatment before cDDP both in vitro and in vivo and suggest that Ro23-7553 may potentiate cDDP cytotoxicity through effects on cell cycle progression.
1 This work was supported by USPHS Grants CA67267 and CA60397 from the National Cancer Institute, NIH.
2 To whom requests for reprints should be addressed, at Department of Otolaryngology, University of Pittsburgh School of Medicine, 203 Lothrop Street, Room 110, Pittsburgh, PA 15213-2582. Phone: (412) 647-6224; Fax: (412) 647-8720; E-mail: candacej@vms.cis.pitt.edu.
Received 4/18/97. Accepted 7/ 7/97.
This article has been cited by other articles:
|
|
 |
|
  Y. Ma, W.-D. Yu, P. A. Hershberger, G. Flynn, R.-X. Kong, D. L. Trump, and C. S. Johnson 1{alpha},25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model Mol. Cancer Ther., September 1, 2008; 7(9): 3047 - 3055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Menezes, R. T. Cheney, A. Husain, M. Tretiakova, G. Loewen, C. S. Johnson, V. Jayaprakash, K. B. Moysich, R. Salgia, and M. E. Reid Vitamin D Receptor Expression in Normal, Premalignant, and Malignant Human Lung Tissue Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1104 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. DeMasters, X. Di, I. Newsham, R. Shiu, and D. A. Gewirtz Potentiation of radiation sensitivity in breast tumor cells by the vitamin D3 analogue, EB 1089, through promotion of autophagy and interference with proliferative recovery. Mol. Cancer Ther., November 1, 2006; 5(11): 2786 - 2797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ma, W.-D. Yu, R.-X. Kong, D. L. Trump, and C. S. Johnson Role of Nongenomic Activation of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathways in 1,25D3-Mediated Apoptosis in Squamous Cell Carcinoma Cells Cancer Res., August 15, 2006; 66(16): 8131 - 8138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Beer, M. Javle, G. N. Lam, W. D. Henner, A. Wong, and D. L. Trump Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer Clin. Cancer Res., November 1, 2005; 11(21): 7794 - 7799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Beer and A. Myrthue Calcitriol in cancer treatment: From the lab to the clinic Mol. Cancer Ther., March 1, 2004; 3(3): 373 - 381. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. A. Norman, R. R. Butrum, E. Feldman, D. Heber, D. Nixon, M. F. Picciano, R. Rivlin, A. Simopoulos, M. J. Wargovich, E. K. Weisburger, et al. The Role of Dietary Supplements during Cancer Therapy J. Nutr., November 1, 2003; 133(11): 3794S - 3799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Muindi, J. W. Wilson, Y. Peng, M. J. Capozolli, C. S. Johnson, and D. L. Trump A Limited Sampling Method for the Estimation of Serum Calcitriol Area under the Curve in Cancer Patients J. Clin. Pharmacol., August 1, 2003; 43(8): 894 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sundaram, A. Sea, S. Feldman, R. Strawbridge, P. J. Hoopes, E. Demidenko, L. Binderup, and D. A. Gewirtz The Combination of a Potent Vitamin D3 Analog, EB 1089, with Ionizing Radiation Reduces Tumor Growth and Induces Apoptosis of MCF-7 Breast Tumor Xenografts in Nude Mice Clin. Cancer Res., June 1, 2003; 9(6): 2350 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Beer, K. M. Eilers, M. Garzotto, M. J. Egorin, B. A. Lowe, and W. D. Henner Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer J. Clin. Oncol., January 1, 2003; 21(1): 123 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Hershberger, T. F. McGuire, W.-D. Yu, E. G. Zuhowski, J. H. M. Schellens, M. J. Egorin, D. L. Trump, and C. S. Johnson Cisplatin Potentiates 1,25-Dihydroxyvitamin D3-induced Apoptosis in Association with Increased Mitogen-activated Protein Kinase Kinase Kinase 1 (MEKK-1) Expression Mol. Cancer Ther., August 1, 2002; 1(10): 821 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Bernardi, D. L. Trump, W.-D. Yu, T. F. McGuire, P. A. Hershberger, and C. S. Johnson Combination of 1{alpha},25-Dihydroxyvitamin D3 with Dexamethasone Enhances Cell Cycle Arrest and Apoptosis: Role of Nuclear Receptor Cross-Talk and Erk/Akt Signaling Clin. Cancer Res., December 1, 2001; 7(12): 4164 - 4173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Prudencio, N. Akutsu, N. Benlimame, T. Wang, Y. Bastien, R. Lin, M. J. Black, M. A. Alaoui-Jamali, and J. H. White Action of Low Calcemic 1{{alpha}},25-Dihydroxyvitamin D3 Analogue EB1089 in Head and Neck Squamous Cell Carcinoma J Natl Cancer Inst, May 16, 2001; 93(10): 745 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Hershberger, W.-D. Yu, R. A. Modzelewski, R. M. Rueger, C. S. Johnson, and D. L. Trump Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity in Vitro and in Vivo and Accelerates Paclitaxel-induced Apoptosis Clin. Cancer Res., April 1, 2001; 7(4): 1043 - 1051. [Abstract] [Full Text]
|
|
|
|
|
|
Q. Wang, W. Yang, M. S. Uytingco, S. Christakos, and R. Wieder 1,25-Dihydroxyvitamin D3 and All-trans-Retinoic Acid Sensitize Breast Cancer Cells to Chemotherapy-induced Cell Death Cancer Res., April 1, 2000; 60(7): 2040 - 2048. [Abstract] [Full Text]
|
|
|
|
|
|
R. M. Korah, V. Sysounthone, Y. Golowa, and R. Wieder Basic Fibroblast Growth Factor Confers a Less Malignant Phenotype in MDA-MB-231 Human Breast Cancer Cells Cancer Res., February 1, 2000; 60(3): 733 - 740. [Abstract] [Full Text]
|
|
|
|
|
|
P. A. Hershberger, R. A. Modzelewski, Z. R. Shurin, R. M. Rueger, D. L. Trump, and C. S. Johnson 1,25-Dihydroxycholecalciferol (1,25-D3) Inhibits the Growth of Squamous Cell Carcinoma and Down-Modulates p21Waf1/Cip1 in Vitro and in Vivo Cancer Res., June 1, 1999; 59(11): 2644 - 2649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Smith, C. S. Johnson, C. C. Freeman, J. Muindi, J. W. Wilson, and D. L. Trump A Phase I Trial of Calcitriol (1,25-Dihydroxycholecalciferol) in Patients with Advanced Malignancy Clin. Cancer Res., June 1, 1999; 5(6): 1339 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Moffatt, W. U. Johannes, and G. J. Miller 1{{alpha}},25-Dihydroxyvitamin D3 and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines Clin. Cancer Res., March 1, 1999; 5(3): 695 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. F. McGuire, D. L. Trump, and C. S. Johnson Vitamin D3-induced Apoptosis of Murine Squamous Cell Carcinoma Cells. SELECTIVE INDUCTION OF CASPASE-DEPENDENT MEK CLEAVAGE AND UP-REGULATION OF MEKK-1 J. Biol. Chem., July 6, 2001; 276(28): 26365 - 26373. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
